Biovitrum AB acquires Cambridge Biotechnology Ltd.
CBT's drug discovery efforts have been focused on obesity, pain and inflammation, utilizing the company's top class scientific and technical skills in the field of cytokine receptors. Cambridge Biotechnology has been highly productive since its formation in 2001, with one compound, CBT 1008 for inflammatory pain, successfully through a phase I clinical trial and generating a pipeline of compounds including novel leptin agonists. The most advanced leptin agonist, for the treatment of obesity, is expected to enter phase I next year. As a subsidiary of Biovitrum, Cambridge Biotechnology will continue to work as an autonomous, highly skilled and innovative R&D unit, based in Cambridge, UK.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.